- Advertisement -
WATERTOWN, Mass.–(BUSINESS WIRE)–Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has received approval from the KRX to proceed with its Initial Public Offering (IPO). The move marks a pivotal…
Click here to view the original article.
